Soligenix updates ATM capacity to $2.96M
Soligenix, Inc. amends its prospectus supplement to set an at-the-market offering capacity of $2,956,000 of common stock under the Sales Agreement with Rodman & Renshaw LLC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Soligenix, Inc. amends its prospectus supplement to set an at-the-market offering capacity of $2,956,000 of common stock under the Sales Agreement with Rodman & Renshaw LLC. The company reports a public float of $24,511,625 based on 17,261,708 shares held by non-affiliates at $1.42 per share as of April 27, 2026. The supplement notes prior sales of $5,214,498 under the Form S-3 instruction during the preceding 12-month period and lists a last reported sale price of $0.87 on May 27, 2026.
Insights
Updated ATM capacity and public float calculations clarify available issuance under the Sales Agreement.
The prospectus supplement adjusts the maximum aggregate offering price to $2,956,000 under an At Market Issuance Sales Agreement with Rodman & Renshaw LLC, tied to the company’s current public float of $24,511,625. This follows General Instruction I.B.6 of Form S-3.
Execution depends on market activity and any future change in public float; further prospectus supplements will be filed if the public float increases and allows additional sales.
Key Figures
Key Terms
At Market Issuance Sales Agreement financial
public float financial
General Instruction I.B.6 regulatory
Form S-3 regulatory
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What amount is Soligenix (SNGX) authorized to sell under the Sales Agreement?
How was the public float calculated for Soligenix's prospectus supplement?
Who is the sales agent for Soligenix’s at-the-market program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-274265
PROSPECTUS SUPPLEMENT
(To Prospectus Supplement dated January 23, 2026
to Prospectus dated December 15, 2023)
Soligenix, Inc.
Up to $2,956,000
COMMON STOCK
This prospectus supplement (the “Prospectus Supplement”) amends and supplements the information in the prospectus supplement dated January 23, 2026 (the “January Prospectus”), filed as a part of our registration statement on Form S-3 (File No. 333-274265) (the “Registration Statement”) and the prospectus dated December 15, 2023 contained therein (the “December Prospectus” and, together with the January Prospectus, the “Prior Prospectus”), relating to the offering, issuance and sale by us of our common stock, par value $0.001 per share, from time to time, that may be issued and sold under the At Market Issuance Sales Agreement (the “Sales Agreement”), dated January 23, 2026, by and between us and Rodman & Renshaw LLC, as sales agent. This Prospectus Supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.
We are filing this Prospectus Supplement to amend the Prior Prospectus to update the maximum dollar amount of shares we are eligible to sell under the Sales Agreement and the Prospectus Supplement. As of the date hereof, the current aggregate market value of our outstanding common stock held by non-affiliates, or public float, is $24,511,625, which was calculated based on 17,261,708 outstanding shares of common stock held by non-affiliates as of such date and a price of $1.42 per share, the last reported sales price of our common stock on April 27, 2026, as reported on the Nasdaq Capital Market.
Pursuant to General Instruction I.B.6, as of the date hereof, we currently may offer and sell common stock having an aggregate offering price of up to $2,956,000 under the Sales Agreement, which amount is in addition to the common stock that we have sold to date in accordance with the Sales Agreement under the Prior Prospectus. If our public float increases such that we may sell additional amounts under the Sales Agreement and the Registration Statement of which this Prospectus Supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional sales. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of the aggregate market value of our common stock held by non-affiliates in any 12 calendar month period, so long as the aggregate market value of our outstanding common stock held by non-affiliates remains below $75 million. As of the date hereof, we have sold securities with an aggregate market value of $5,214,498 pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.
Our common stock is listed on the Nasdaq Capital Market under the symbol “SNGX.” On May 27, 2026, the last reported sale price of our common stock on the Nasdaq Capital Market was $0.87 per share.
We are a smaller reporting company as defined under Rule 405 of the Securities Act of 1933, as amended, and as such, we have elected to comply with certain reduced public company reporting requirements. See the section entitled
“Summary — Implications of Being a Smaller Reporting Company” on page S-3 of the Prior Prospectus for additional information.
Investing in our common stock involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our common stock in “Risk Factors” beginning on page S-7 of the Prior Prospectus, and in our most recent Annual Report on Form 10-K and in the risks discussed under similar headings in the documents incorporated by reference in this Prospectus Supplement and the Prior Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prior Prospectus or this Prospectus Supplement. Any representation to the contrary is a criminal offense.
Rodman & Renshaw LLC
The date of this Prospectus Supplement is May 28, 2026.